Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies

Breast Cancer Research and Treatment

Volumn 148, Issue 1, 2014, Pages 143-151

  Salmen, Jessica ^a   Neugebauer, Julia ^b   Fasching, Peter A ^c,h   Haeberle, Lothar ^c   Huober, Jens ^a   Wöckel, Achim ⁱ   Rauh, Claudia ^c   Schuetz, Florian ^d   Weissenbacher, Tobias ^b   Kost, Bernd ^b   Stickeler, Elmar ^e   Klar, Maximilian ^e   Orlowska Volk, Marzenna ^e   Windfuhr Blum, Marisa ^e   Heil, Joerg ^d   Rom, Joachim ^d   Sohn, Christof ^d   Fehm, Tanja ^f,g   Mohrmann, Svjetlana ^f   Loehberg, Christian R ^c   Hein, Alexander ^c   Schulz Wendtland, Ruediger ^c   Hartkopf, Andreas D ^g   Brucker, Sara Y ^g   Wallwiener, Diethelm ^g   Friese, Klaus ^b   Hartmann, Arndt ^c   Beckmann, Matthias W ^c   Janni, Wolfgang ^a   Rack, Brigitte ^b   more..

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ University Medicine of Würzburg   (Germany)

Author keywords

Breast cancer; Interaction; Progesterone receptor; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SEX HORMONE ANTAGONIST; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CORRELATIONAL STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; DISTANT METASTASIS FREE SURVIVAL; FEMALE; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ONSET AGE; OVERALL SURVIVAL; PERFORMANCE MEASUREMENT SYSTEM; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TISSUE DISTRIBUTION; TUMOR VOLUME; AGED; BIOSYNTHESIS; BREAST TUMOR; GERMANY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL;

ADULT; AGED; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84922002641     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3130-4     Document Type: Article

References (43)

1. Eisemann N, Waldmann A, Katalinic A (2013) Epidemiology of Breast Cancer - Current Figures and Trends. Geburtsh Frauenheilk 73(2):130–135. doi:10.1055/s-0032-1328075
2. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ, Panel M (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206–2223. doi:10.1093/annonc/mdt303
3. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21(10):1973–1979. doi:10.1200/JCO.2003.09.099
4. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29(32):4273–4278. doi:10.1200/JCO.2010.31.2835
5. Obr AE, Edwards DP (2012) The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol 357(1–2):4–17. doi:10.1016/j.mce.2011.10.030
6. Ismail PM, Li J, DeMayo FJ, O’Malley BW, Lydon JP (2002) A novel LacZ reporter mouse reveals complex regulation of the progesterone receptor promoter during mammary gland development. Mol Endocrinol 16:2475–2489
7. Shyamala G, Chou YC, Louie SG, Guzman RC, Smith GH, Nandi S (2002) Cellular expression of estrogen and progesterone receptors in mammary glands: regulation by hormones, development and aging. J Steroid Biochem Mol Biol 80:137–148
8. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320):98–102. doi:10.1038/nature09387
9. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R (2010) Progesterone induces adult mammary stem cell expansion. Nature 465(7299):803–807. doi:10.1038/nature09091
10. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE (2010) Control of mammary stem cell function by steroid hormone signalling. Nature 465(7299):798–802. doi:10.1038/nature09027
11. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider P, Brisken C (2010) Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 107(7):2989–2994. doi:10.1073/pnas.0915148107
12. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM (2000) The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103(1):41–50
13. Medina D, Kittrell FS, Shepard A, Stephens LC, Jiang C, Lu J, Allred DC, McCarthy M, Ullrich RL (2002) Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB J 16:881–883
14. Medina D, Kittrell FS, Shepard A, Contreras A, Rosen JM, Lydon J (2003) Hormone dependence in premalignant mammary progression. Cancer Res 63:1067–1072
15. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28(3):509–518. doi:10.1200/JCO.2009.23.1274
16. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. doi:10.1016/S0140-6736(11)60993-8
17. Luftner D, Lux MP, Maass N, Schutz F, Schwidde I, Fasching PA, Fehm T, Janni W, Kummel S, Kolberg HC (2012) Advances in Breast Cancer - Looking Back over the Year. Geburtsh Frauenheilk 72(12):1117–1129. doi:10.1055/s-0032-1328084
18. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M (2005) Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: an Hypothesis-Generating Study. J Clin Oncol 23:7512–7517
19. Hoefnagel LD, Moelans CB, Meijer SL, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van Gils CH, van der Wall E, van Diest PJ (2012) Prognostic value of estrogen receptor alpha and progesterone receptor conversion in distant breast cancer metastases. Cancer. doi:10.1002/cncr.27518
20. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van der Groep P, de Vries EG, van der Wall E, van Diest PJ (2010) Receptor conversion in distant breast cancer metastases. Breast Cancer Res 12(5):R75. doi:10.1186/bcr2645
21. Harrell FE Jr, Lee KL, Pollock BG (1988) Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst 80(15):1198–1202
22. Sauerbrei W, Schumacher M (1992) A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11(16):2093–2109
23. Simon R, Altman DG (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69(6):979–985
24. Grambsch PM, Therneau TM (1994) Proportional Hazards Tests and Diagnostics Based on Weighted Residuals. Biometrika 81(3):515–526
25. Chambless LE, Diao G (2006) Estimation of time-dependent area under the ROC curve for long-term risk prediction. Stat Med 25(20):3474–3486. doi:10.1002/sim.2299
26. Gronnesby JK, Borgan O (1996) A method for checking regression models in survival analysis based on the risk score. Lifetime Data Anal 2(4):315–328
27. Liu S, Chia SK, Mehl E, Leung S, Rajput A, Cheang MC, Nielsen TO (2010) Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 119(1):53–61. doi:10.1007/s10549-009-0318-0
28. Yang LH, Tseng HS, Lin C, Chen LS, Chen ST, Kuo SJ, Chen DR (2012) Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients. J Breast Cancer 15(3):288–295. doi:10.4048/jbc.2012.15.3.288
29. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO (2007) Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 25(30):4772–4778. doi:10.1200/JCO.2007.12.2747
30. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Iorfida M, Mazza M, Balduzzi A, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M (2012) Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol. doi:10.1093/annonc/mds430
31. Rosen JM (2003) Hormone receptor patterning plays a critical role in normal lobuloalveolar development and breast cancer progression. Breast Dis 18:3–9
32. Brisken C, Rajaram RD (2006) Alveolar and lactogenic differentiation. J Mammary Gland Biol Neoplasia 11(3–4):239–248. doi:10.1007/s10911-006-9026-0
33. Brisken C (2002) Hormonal control of alveolar development and its implications for breast carcinogenesis. J Mammary Gland Biol Neoplasia 7(1):39–48. doi:10.1023/A:1015718406329
34. Anderson E (2002) The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 4(5):197–201
35. Shoker BS, Jarvis C, Clarke RB, Anderson E, Munro C, Davies MP, Sibson DR, Sloane JP (2000) Abnormal regulation of the oestrogen receptor in benign breast lesions. J Clin Pathol 53(10):778–783
36. Sutherland RL, Prall OW, Watts CK, Musgrove EA (1998) Estrogen and progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia 3(1):63–72. doi:10.1023/A:1018774302092
37. Skildum A, Faivre E, Lange CA (2005) Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol 19(2):327–339. doi:10.1210/me.2004-0306
38. Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, Sclafani RA, Lange CA, Horwitz KB (1997) Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol 11(11):1593–1607
39. Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI, Reddel RR, Clarke CL (2009) DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 150(7):3318–3326. doi:10.1210/en.2008-1630
40. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360(8):790–800. doi:10.1056/NEJMra0801289
41. Strehl JD, Wachter DL, Fasching PA, Beckmann MW, Hartmann A (2011) Invasive Breast Cancer: recognition of Molecular Subtypes. Breast Care (Basel) 6(4):258–264. doi:10.1159/000331339
42. Schmidt M, Fasching PA, Beckmann MW, Kolbl H (2012) Biomarkers in Breast Cancer–an Update. Geburtsh Frauenheilk 72(9):819–832. doi:10.1055/s-0032-1315340
43. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795. doi:10.1200/JCO.2009.25.6529